Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

Ardelyx Inc. Stock

Price
Target price
€6.04

€6.04

2.370%
0.14
2.370%
€15.50
 
10:48 / Tradegate WKN: A116X0 / Name: Ardelyx / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Ardelyx Inc. in the next few years
Wizard

Description Ardelyx

Ardelyx is a biopharmaceutical company listed on the NASDAQ stock exchange under the ticker symbol "ARDX". The company was founded in 2007 and is headquartered in Fremont, California.

Ardelyx specializes in the development of innovative treatments for cardio-renal and gastrointestinal diseases. The company's lead product candidate is tenapanor, a small molecule that targets the sodium-hydrogen exchanger 3 (NHE3) transporter in the gastrointestinal tract. Tenapanor is being developed as a treatment for hyperphosphatemia in patients with end-stage renal disease who are on dialysis.

In addition to tenapanor, Ardelyx has a number of other product candidates in its pipeline, including RDX013 and RDX009, which are being developed as treatments for hyperkalemia and inflammatory bowel disease, respectively.

Ardelyx went public in 2014 and has since raised significant capital to fund its research and development efforts. The company has partnerships with a number of pharmaceutical companies, including Kyowa Kirin and Sanofi. As of September 2021, Ardelyx had a market capitalization of approximately $255 million.

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Ardelyx Inc. is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Ardelyx

sharewise wants to provide you with the best news and tools for Ardelyx, so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Why Ardelyx Stock Soared Today: https://g.foolcdn.com/editorial/images/753108/green-arrow-up-stock-chart.jpg
Why Ardelyx Stock Soared Today

Shares of Ardelyx (NASDAQ: ARDX) were up 9.5% as of 3:47 p.m. after the biotech company announced better-than-expected third-quarter 2023 results.

Ardelyx's quarterly revenue skyrocketed to $56.4

TheMotleyFool 
0 31.10.23
3 mid-caps under $20 that Wall Street loves: https://www.marketbeat.com/logos/articles/med_20240122191242_3-mid-caps-under-20-that-wall-street-loves.jpg
3 mid-caps under $20 that Wall Street loves

Just three trading weeks into the new year, a half dozen U.S. mid- or large-cap stocks are already up 20% or more.

Picking up where it left off last year, artificial intelligence (AI) data center

MarketBeat 
0 23.01.24